The scavenger receptor-A (SR-A), originally recognized by its ability to internalize modified lipoproteins, has largely been studied in relation to atherosclerosis as well as innate immunity against pathogen infection. SR-A was recently shown to be a receptor on antigen-presenting cell for heat shock protein (HSP) and was implicated in the crosspresentation of HSP-chaperoned antigens. Here, we show that SR-A is not required for antitumor immunity generated by HSP-based (e.g., grp170) vaccine approaches in vivo.
Introduction
Scavenger receptor-A (SR-A), also known as CD204, is the first cloned member of an expanding family of structurally diverse receptors collectively termed scavenger receptors (1) . SR-A is expressed primarily on the innate immune cells [e.g., macrophages (M$) and dendritic cells] and functions as a pattern recognition receptor (PRR). SR-A is able to bind a broad range of ligands, including chemically modified or altered molecules, bacterial surface components [e.g., lipopolysaccharide (LPS)], and apoptotic cells (2) . SR-A has been studied extensively in the context of atherosclerosis, where it was identified initially as a major receptor on M$ for internalization of oxidative or acylated low-density lipoproteins (3) (4) (5) . Suzuki et al. (4) and Thomas et al. (6) have reported that SR-A À/À mice have impaired protection against pathogen infection. The nature of the protective mechanism provided by SR-A is not fully defined. However, SR-A-deficient mice are more susceptible to endotoxic mortality caused by overproduction of proinflammatory cytokines [e.g., tumor necrosis factor-a (TNF-a)] by activated M$ (7) . Recent studies from Kobzik and Platt's groups suggest that SR-A may act as an inhibitory receptor in proinflammatory responses (8, 9) . Therefore, the capability of SR-A to recognize pathogen-related molecules and suppress cytokine responses to bacterial component may explain, at least in part, increased mortality in the infected SR-A knockout (SR-A À/À ) mice. Although a large body of information is accumulating about the role of SR-A in atherosclerosis and pathogen recognition, the contribution of this receptor to antigen-specific antitumor immunity has not been explored.
Stress proteins, also called heat shock proteins (HSP), mainly act as molecular chaperones in a variety of cellular functions under physiologic as well as stress conditions. The immunologic roles of HSPs have been extensively studied because Srivastava et al. (10) discovered that tumor-derived HSPs are capable of eliciting a potent antitumor response. A large body of evidence supports the idea of using HSPs for vaccine design because of its unique abilities to act as both an antigen carrier and an immune modulator (11) . Recently, several surface receptors on antigen-presenting cells (APC), including SR-A, have been implicated in the HSP-mediated cross-priming event (12, 13) . However, the involvement of SR-A in HSP vaccine-generated antitumor immunity has not been well characterized.
In the present study, we report that HSP-mediated (i.e., grp170) antitumor activities not only remain intact but also are enhanced in SR-A knockout mice (SR-A À/À ). Further, the absence of SR-A can restore the immunogenicity of poorly immunogenic tumors and significantly improve the antitumor efficacy of vaccines using Tolllike receptor (TLR) agonists as adjuvants. Consequently, SR-A seems capable of dampening the immunostimulatory effects derived from adjuvants of both mammalian and nonmammalian origins. Our studies suggest that SR-A plays an important role in regulating the antigen-presenting capability of APCs, thereby affecting the induction of an antigen-specific CTL response and antitumor immunity.
Materials and Methods
Mice and cell lines. Wild-type (WT) C57BL/6 mice were purchased from The Jackson Laboratory. SR-A knockout mice (4), provided by Mason W. Tumor studies. Tumor-derived grp170 was purified from culture medium of B16-sgrp170 cells as described previously (14) . Recombinant gp100 and grp170 protein were expressed using baculovirus-insect cell system (15) . gp100-grp170 chaperone complex was generated by incubating gp100 and grp170 at an equal molar ratio under heat shock conditions as described previously (15, 16) . For tumor challenge study, mice were immunized s.c. with irradiated tumor cells (1 Â 10 6 ), tumor-derived grp170 (30 Ag), and gp100-grp170 complex (30 Ag) in the left flank. Two weeks after immunization, mice were challenged by i.d. injections of 2 Â 10 5 live tumor cells into the right flank. In some experiments, mice were immunized with recombinant gp100 (30 Ag) or gp100 emulsified in complete Freund's adjuvant (CFA; Sigma-Aldrich) or mixed with 5 Ag LPS (Escherichia coli serotype 026:B6; Sigma-Aldrich). For therapeutic studies, mice were inoculated with 2 Â 10 5 D121 tumor cells on day 0 followed by treatment with irradiated D121 cells on days 2, 4, 6, and 8. The tumor volume was calculated using the following formula: V = (the shortest diameter 2 Â the longest diameter) / 2. Depletion of CD4 + and CD8 + T-cell subsets was accomplished by i.p. injection of GK1.5 and 2.43 monoclonal antibody, respectively, as described previously (16) . For inhibition of phagocytic cells, 1 mg carrageenan (type II; Sigma-Aldrich) in 200 AL PBS was administered by i.p. (17) .
Enzyme-linked immunosorbent spot and CTL assay. Splenocytes were isolated from immunized mice 2 weeks after immunization and stimulated with 1 Ag/mL H-2K b -restricted CTL epitope OVA 257-264 (SIINFEKL) or irrelevant E7 49-57 (RAHYNIVTF) to determine antigenspecific IFN-g-secreting T cells as described previously (16) . For CTL assay, splenocytes were stimulated with 1 Amol/L OVA 257-264 in the presence of interleukin (IL)-2 (20 units/mL) for 5 days. CD8 + T cells were isolated by magnetic-activated cell sorting CD8 (Ly-2) microbeads (Miltenyi Biotec) and used as effector cells in a chromium release assay as described (16) .
Cytokine assay. Dendritic cells were generated from mouse bone marrow in the presence of granulocyte macrophage colony-stimulating factor (20 ng/mL; BD Biosciences) and IL-4 (10 ng/mL; BD Biosciences) as described previously (18) . For cytokine assay, 1Â 10 6 day 7 dendritic cells were cultured in the presence of LPS or with irradiated tumor cells for 24 h. Irradiated tumor cells were cultured in serum-free medium for 24 h before use. The supernatants were harvested for measuring TNF-a using ELISA kits (eBioscience).
B3Z T-cell activation assay. Day 7 bone marrow dendritic cells were pulsed with OVA 257-264 (SIINFEKL) at 37jC for 1 h and washed thrice with PBS. Alternatively, dendritic cells were cocultured with irradiated cells and isolated using CD11c microbeads (Miltenyi Biotec). Following stimulation with LPS, dendritic cells were coincubated overnight at 37jC with 1 Â 10 5 B3Z T cells, which carry a lacZ (h-galactosidase) construct driven by nuclear factor of activated T-cell elements from the IL-2 promoter and recognize OVA in the context of K b MHC class I molecules. Cell pellets were lysed with PBS containing 0.125% NP40 and 1 mmol/L chromophenol red h-galactoside (Calbiochem). Plate was read at 570 nm using a 96-well plate reader with 630 nm as reference wavelength. The response of LacZinducible B3Z T cells was measured as absorbance of the colored product generated by cleavage of the LacZ substrate chromophenol red h-galactoside.
Results
SR-A is not essential for grp170 vaccine-generated antitumor immunity. Our previous studies have shown that grp170, the largest endoplasmic reticulum chaperone, possesses highly potent immunostimulatory properties (15, 19) . More recently, we showed that B16 tumor cell expressing a secretory form of grp170 (B16-sgrp170) was an effective vaccine generating an antitumor response in WT C57BL6 mice (14) . Therefore, using SR-A knockout mice, we sought to address the question whether the absence of SR-A may negatively affect the immunogenicity of B16-sgrp170 cell vaccine. Both WT and SR-A À/À C57BL/6 mice were immunized with irradiated parental B16 cells and B16-sgrp170 cells or left untreated followed by tumor challenge. Consistent with our earlier report, WT mice without immunization and those immunized with irradiated B16 cells developed aggressively growing tumors on tumor challenge, whereas WT mice immunized with irradiated B16-sgrp170 were partially protected (Fig. 1A) . Strikingly, although tumors grew in the untreated SR-A À/À mice similarly to those in WT mice, all tumors inoculated in SR-A À/À mice vaccinated with either irradiated B16 cell or irradiated B16-sgrp170 were rejected (Fig. 1B) . Two other grp170-based vaccine approaches were subsequently evaluated: grp170 purified from B16-sgrp170 cells (i.e., the conventional tumor-derived HSP vaccine) and grp170 complexed with a well-characterized melanoma-associated antigen gp100 (i.e., a reconstituted chaperone vaccine recently developed by our group; Fig. 1C and D) . After immunization, mice were challenged with B16 tumor cells that naturally express gp100. Both types of grp170 vaccine formulations (i.e., purified from tumor or in vitro Figure 3 . SR-A deficiency enhances antitumor immunity generated by gp100 formulated with non-HSP adjuvants. WT or SR-A À/À mice (n = 10) were immunized with gp100 protein, gp100 emulsified in CFA, or gp100 mixed with LPS followed by tumor challenge with B16 cells 2 wks later (P < 0.001, log-rank test, immunized SR-A À/À versus immunized WT mice).
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However, gp100 protein emulsified in CFA or mixed with LPS protected SR-A À/À mice, not WT mice, from B16 tumor challenge (Fig. 3) . Interestingly, priming of animals with gp100 protein emulsified in incomplete Freund's adjuvant did not generate antitumor responses in both WT and SR-A À/À mice (data not shown), suggesting that immunostimulatory mycobacterial components are required for the highly potent vaccine activity in SR-A À/À mice.
Enhanced CD8 + T-cell response in SR-A À/À mice compared with WT mice. A clue that there may be involvement of immune effector cells in the enhanced tumor rejection in SR-A À/À mice was Figure 4 . The enhanced antitumor immunity in SR-A À/À mice is associated with a robust CTL response. A, depletion of T-cell subsets and phagocytes was done by antibody injections. SR-A À/À mice (n = 10) were immunized with irradiated D121 cells followed by D121 tumor challenge (P < 0.001, CD8
+ T-cell depletion or carrageenan group versus IgG group). B, increased antigen-specific CD8 + T-cell frequency in SR-A À/À mice. Following immunization with irradiated B16-OVA cells, splenocytes were stimulated with or without OVA 257-264 . IFN-g production was measured using an enzyme-linked immunosorbent spot (ELISPOT ) assay. *, P < 0.01, Student's t test. C, splenocytes from mice immunized with OVA-CFA were stimulated with OVA 257-264 or E7 49-57 and subjected to ELISPOT assay. D, splenocytes from OVA-CFA-immunized mice were restimulated with OVA 257-264 in vitro. The CD8 + T cells were analyzed for cytotoxic activity using 51 Cr-labeled B16-OVA as targets. were separated on a 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. Expression of SR-A was detected using SR-A-specific rabbit polyclonal antibodies (1:10,000). B, dendritic cells from WT or SR-A À/À mice were stimulated with or without LPS and subjected to immunoblotting. C and D, day 7 bone marrow dendritic cells (DC ) were cultured in 24-well plate with 10 ng/mL LPS (C ) or irradiated D121 cells (D) at a 1:5 ratio for 24 h. NS, no stimulation. The supernatants were measured for secretion of TNF-a using ELISA. *, P < 0.01, Student's t test.
determined by antibody depletion studies in vivo (Fig. 4A) . Elimination of CD8 + T cells completely abrogated tumor protective immunity, whereas lack of CD4 + T cells had no effect. Carrageenan, which impairs function of phagocytic cells, also diminished the antitumor response, indicating an important role of phagocytes (e.g., M$ and dendritic cells) in antigen capture and immune initiation.
Given that CD8 + T cells were involved in the tumor rejection in SR-A À/À mice, we next determined the effect of SR-A deficiency on vaccination-elicited antigen-specific CTL response. Splenocytes were isolated from mice immunized with irradiated B16 cell transfected with a model antigen OVA. On stimulation with the MHC I-restricted OVA 257-264 (SIINFEKL) peptide, splenocytes derived from SR-A À/À mice displayed a robust production of IFN-g in comparison with those from immunized WT mice (Fig. 4B) . Moreover, splenocytes from OVA-CFA-immunized SR-A À/À mice produced higher levels of IFN-g than did WT cells after stimulation with OVA 257-264 peptide, not irrelevant E7 peptide, indicating an antigen specificity of the primed CTLs (Fig. 4C) . Effector CD8 + -T-cell function (i.e., cytolytic activity), as assessed by chromium release assay, was also enhanced in the immunized SR-A À/À mice (Fig. 4D ).
Using standard surface markers, fluorescence-activated cell sorting (FACS) analyses were carried out to assess the potential effect of SR-A deficiency on cellular composition of the immune compartments. Naive SR-A À/À mice showed normal lymphocyte composition (e.g., B-cell, T-cell, and T-cell subtype) in spleen and lymph nodes, with numbers and ratios of CD4 + and CD8 + T cells in the periphery that were not different from those of WT mice (data not shown). In addition, there were no substantial differences between mitogen-stimulated proliferation response of naive T cells derived from WT and SR-A À/À mice (data not shown).
SR-A-deficient APCs are more responsive to inflammatory stimuli. Examination of SR-A expression in various cell types by immunoblotting showed that SR-A was present primarily in professional phagocytes or APCs (e.g., dendritic cell and M$), whereas SR-A is absent or undetectable in B16 tumor cells and Miltenyi microbeads isolated T and B cells (Fig. 5A) . Further, it was seen that SR-A expression increased in LPS-treated WT bone marrow dendritic cells (Fig. 5B) .
When stimulated with LPS, bone marrow dendritic cells from SR-A À/À mice produced more TNF-a and IL-6 (data not shown) than did WT counterparts (Fig. 5C ). SR-A À/À dendritic cells also exhibited a more mature phenotype on LPS stimulation, indicated by surface staining with MHC II and CD86 antibodies (data not shown). In addition, the enhanced production of TNF-a (Fig. 5D ) was observed when bone marrow dendritic cells from SR-A (Fig. 6B ).
Discussion
The recent report of SR-A as a binding receptor for grp94/gp96, an extensively studied immunoadjuvant (13), prompted investigation of whether SR-A is involved in HSP-mediated antitumor effects in vivo. We made an unexpected observation that the antitumor response elicited by various grp170-based vaccines was enhanced in SR-A genetically deficient mice. Although more studies are required to determine the involvement of SR-A in other HSPmediated immune activities, these findings suggest that SR-A may not be essential for in vivo presentation of HSP-associated antigens or subsequent antitumor immunity. It is conceivable that the presence of other redundant endocytic receptors or HSP receptors (e.g., SREC, LOX-1, and CD91) on APCs may sufficiently compensate for the loss of SR-A in vivo. More importantly, we have shown that vaccines formulated with either HSP or non-HSP (e.g., CFA and mice, suggesting that SR-A is capable of dampening the immunostimulatory activities derived from adjuvants of both mammalian and nonmammalian origins. Although LPS is a wellrecognized TLR4 ligand, the immunostimulatory properties of HSPs (22, 23) and CFA (24) have been attributed to the TLR2/TLR4 signaling pathways. Thus, SR-A seems to attenuate the adjuvant effects provided by the activation of TLR signaling.
The significance of TLR signaling in enhancing antigen presentation and activating adaptive or acquired immune responses has been well established (25) . The engagement of TLR signaling pathways is a promising mechanism for boosting vaccine responses against infectious diseases as well as cancer (26, 27) . The action mechanism of the exogenous adjuvants or the nonmammalian microbial pattern molecules (e.g., LPS) can be depicted by the ''stranger hypothesis'' (28) . In addition, the ''danger hypothesis'' proposes that the immune system can discriminate endogenous ''danger'' molecules released from injured host cells, which are distinct from the exogenous adjuvants of microbes (29) . Indeed, these endogenous damage-associated molecular pattern molecules, including HSPs, signal through the same TLRs and the downstream MyD88/nuclear factor-nB pathway as those used by nonmammalian microbial pattern molecules (30) (31) (32) (33) (34) . Therefore, TLRs are important in recognition of danger molecules generated from self or infectious materials and are representative adjuvant receptors. The inhibition of adjuvant effects of TLR agonists as shown by both in vivo and in vitro studies here further underscores the important role of SR-A in immune modulation.
In the present study, we have shown that SR-A is preferentially expressed in professional APCs, and dendritic cells derived from SR-A-deficient mice are highly responsive to inflammatory stimuli, such as LPS and ionizing radiation-damaged cells. These results agree with the previously reported roles of SR-A in inhibiting production of proinflammatory cytokines by LPS-activated M$ (7, 8) , supporting the idea that SR-A may act as an inhibitory receptor to limit proinflammatory responses. The Platt group recently showed that SR-A À/À dendritic cells displayed enhanced expression of TNF-a and costimulatory molecule CD40 on LPS stimulation, suggesting that SR-A might be a limiting factor in dendritic cell maturation (9) . Interestingly, the enhanced production of IL-6 and TNF-a by SR-A À/À dendritic cells was also observed when cocultured with dying tumor cells. Identities of the molecules in dying cells that stimulate dendritic cells to release inflammatory mediators are not clear. However, endogenous danger molecules, such as stress/HSPs, are likely to be the candidates. APCs, particularly dendritic cells, can sense pathogens or ''dangers'' through PRRs and direct the immune system to initiate appropriate and effective responses. The default action of dendritic cells in antigen cross-presentation is likely to promote tolerance, or partial activation, in the absence of inflammatory signals or costimulation (35) . Given that the decision between T-cell immunity and tolerance is decided in part by the activation state of dendritic cells, the lack of SR-A may enhance the maturation and activation of dendritic cells by endogenous or exogenous inflammatory stimuli or danger signals, which leads to improved antigen presentation and tumor immunity. Furthermore, the enhanced IL-6 production by SR-A À/À dendritic cells may block the suppressive effect of CD4 + CD25 + regulatory T cells, facilitating the development of type 1 immunity in vivo (26) .
The present study also raises the question of how SR-A may regulate TLR signaling at the molecular levels. We have shown no significant difference between WT and SR-A À/À dendritic cells in the uptake of dying cells or grp170 (data not shown). Similar observations have been made in the case for LPS clearance in SR-A À/À mice (7, 36) . Thus, the contribution of SR-A to the removal of the inflammatory molecules may not play a major role in SR-Amediated immune-suppressive effects. The similar expression of CD14, TLR2/TLR4, and MD-2 on SR-A À/À dendritic cells and WT counterparts also indicates that SR-A deficiency does not result in changes in TLR signaling receptors (9) . Earlier studies suggested that SR-A is linked directly to signal transduction pathways (37-39). Kobzik's group recently showed that engagement of SR-A triggered production of H 2 O 2 , a signaling messenger, and inhibited release of IL-12 by M$ (40) . The physical or functional interactions between SR-A and the TLR signaling pathway, therefore, are likely to play a key role in the immunoregulation by SR-A. In summary, the abilities of SR-A to attenuate adjuvantgenerated (e.g., TLR agonist) immunostimulatory effects suggest that SR-A represents a previously unrecognized immune-suppressive receptor, participating in maintenance of host immune homeostasis. To improve vaccine efficacy and achieve ultimate success in cancer immunotherapy, novel strategies must be developed to overcome the various inherent negative regulatory mechanisms. Selective removal or blockade of SR-A (e.g., using a RNA silencing technology or soluble decoy receptors) may be a promising approach to enhance antigen-specific immune responses. Further dissection of the global contribution of SR-A to the host immunity or tolerance and unraveling the details of inflammatory pathways modulated by the innate PRR will facilitate the design of SR-A-targeted approaches for treatment of cancer.
